Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers

被引:7
作者
Borde, Julika [1 ]
Laitman, Yael [2 ,3 ]
Bluemcke, Britta [1 ]
Niederacher, Dieter [4 ]
Weber-Lassalle, Konstantin [1 ]
Sutter, Christian [5 ]
Rump, Andreas [6 ]
Arnold, Norbert [7 ]
Wang-Gohrke, Shan [8 ]
Horvath, Judit [9 ]
Gehrig, Andrea [10 ]
Schmidt, Gunnar [11 ]
Dutrannoy, Veronique [12 ]
Ramser, Juliane [13 ]
Hentschel, Julia [14 ]
Meindl, Alfons [15 ]
Schroeder, Christopher [16 ]
Wappenschmidt, Barbara
Engel, Christoph [17 ]
Kuchenbaecker, Karoline [18 ,19 ]
Schmutzler, Rita K. [1 ]
Friedman, Eitan [2 ,3 ]
Hahnen, Eric [1 ]
Ernst, Corinna [1 ]
机构
[1] Univ Hosp Cologne, Med Fac, Ctr Familial Breast & Ovarian Canc, Ctr Integrated Oncol CIO, Kerpener Str 62, D-50937 Cologne, Germany
[2] Sheba Med Ctr, Oncogenet Unit, Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[4] Heinrich Heine Univ, Univ Hosp Duesseldorf, Dept Obstet & Gynaecol, Dusseldorf, Germany
[5] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany
[6] Tech Univ Dresden, Inst Clin Genet, Dresden, Germany
[7] Christian Albrechts Univ Kiel, Univ Hosp Schleswig Holstein, Inst Clin Mol Biol, Dept Obstet & Gynaecol, Campus Kiel, Kiel, Germany
[8] Univ Hosp Ulm, Dept Obstet & Gynaecol, Ulm, Germany
[9] Univ Hosp Muenster, Inst Human Genet, Munster, Germany
[10] Julius Maximilians Univ, Inst Human Genet, Wurzburg, Germany
[11] Hannover Med Sch, Inst Human Genet, Hannover, Germany
[12] Charite Univ Med Berlin, Inst Med & Human Genet, Berlin, Germany
[13] Tech Univ Munich, Div Tumor Genet, Dept Gynaecol & Obstet, Klinikum Rechts Isar, Munich, Germany
[14] Univ Leipzig Hosp & Clin, Inst Human Genet, Leipzig, Germany
[15] Univ Hosp Munich, Dept Gynaecol & Obstet, LMU Munich, Munich, Germany
[16] Univ Tubingen, Inst Med Genet & Appl Genom, Tubingen, Germany
[17] Inst Med Informat Stat & Epidemiol IMISE, Leipzig, Germany
[18] UCL, Div Psychiat, London, England
[19] UCL, UCL Genet Inst, London, England
关键词
Breast cancer; Polygenic risk score; PRS; Risk assessment; BRCA1; BRCA2; HEREDITARY BREAST; FAMILY-HISTORY; OVARIAN; MUTATIONS; ASSOCIATION; PREDICTION; MODIFIERS; WOMEN; LIFE;
D O I
10.1186/s12885-022-09780-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Clinical management of women carrying a germline pathogenic variant (PV) in the BRCA1/2 genes demands for accurate age-dependent estimators of breast cancer (BC) risks, which were found to be affected by a variety of intrinsic and extrinsic factors. Here we assess the contribution of polygenic risk scores (PRSs) to the occurrence of extreme phenotypes with respect to age at onset, namely, primary BC diagnosis before the age of 35 years (early diagnosis, ED) and cancer-free survival until the age of 60 years (late/no diagnosis, LD) in female BRCA1/2 PV carriers. Methods Overall, estrogen receptor (ER)-positive, and ER-negative BC PRSs as developed by Kuchenbaecker et al. for BC risk discrimination in female BRCA1/2 PV carriers were employed for PRS computation in a curated sample of 295 women of European descent carrying PVs in the BRCA1 (n=183) or the BRCA2 gene (n=112), and did either fulfill the ED criteria (n=162, mean age at diagnosis: 28.3 years, range: 20 to 34 years) or the LD criteria (n=133). Binomial logistic regression was applied to assess the association of standardized PRSs with either ED or LD under adjustment for patient recruitment criteria for germline testing and localization of BRCA1/2 PVs in the corresponding BC or ovarian cancer (OC) cluster regions. Results For BRCA1 PV carriers, the standardized overall BC PRS displayed the strongest association with ED (odds ratio (OR) = 1.62; 95% confidence interval (CI): 1.16-2.31, p<0.01). Additionally, statistically significant associations of selection for the patient recruitment criteria for germline testing and localization of pathogenic PVs outside the BRCA1 OC cluster region with ED were observed. For BRCA2 PV carriers, the standardized PRS for ER-negative BC displayed the strongest association (OR = 2.27, 95% CI: 1.45-3.78, p<0.001). Conclusions PRSs contribute to the development of extreme phenotypes of female BRCA1/2 PV carriers with respect to age at primary BC diagnosis. Construction of optimized PRS SNP sets for BC risk stratification in BRCA1/2 PV carriers should be the task of future studies with larger, well-defined study samples. Furthermore, our results provide further evidence, that localization of PVs in BC/OC cluster regions might be considered in BC risk calculations for unaffected BRCA1/2 PV carriers.
引用
收藏
页数:9
相关论文
共 37 条
  • [1] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [2] BAMClipper: removing primers from alignments to minimize false-negative mutations in amplicon next-generation sequencing
    Au, Chun Hang
    Ho, Dona N.
    Kwong, Ava
    Chan, Tsun Leung
    Ma, Edmond S. K.
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [3] GenABEL: an R library for genome-wide association analysis
    Aulchenko, Yurii S.
    Ripke, Stephan
    Isaacs, Aaron
    Van Duijn, Cornelia M.
    [J]. BIOINFORMATICS, 2007, 23 (10) : 1294 - 1296
  • [4] Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
    Barnes, Daniel R.
    Rookus, Matti A.
    McGuffog, Lesley
    Leslie, Goska
    Mooij, Thea M.
    Dennis, Joe
    Mavaddat, Nasim
    Adlard, Julian
    Ahmed, Munaza
    Aittomaki, Kristiina
    Andrieu, Nadine
    Andrulis, Irene L.
    Arnold, Norbert
    Arun, Banu K.
    Azzollini, Jacopo
    Balmana, Judith
    Barkardottir, Rosa B.
    Barrowdale, Daniel
    Benitez, Javier
    Berthet, Pascaline
    Bialkowska, Katarzyna
    Blanco, Amie M.
    Blok, Marinus J.
    Bonanni, Bernardo
    Boonen, Susanne E.
    Borg, Ake
    Bozsik, Aniko
    Bradbury, Angela R.
    Brennan, Paul
    Brewer, Carole
    Brunet, Joan
    Buys, Saundra S.
    Caldes, Trinidad
    Caligo, Maria A.
    Campbell, Ian
    Christensen, Lise Lotte
    Chung, Wendy K.
    Claes, Kathleen B. M.
    Colas, Chrystelle
    Collonge-Rame, Marie-Agnes
    Cook, Jackie
    Daly, Mary B.
    Davidson, Rosemarie
    de la Hoya, Miguel
    de Putter, Robin
    Delnatte, Capucine
    Devilee, Peter
    Diez, Orland
    Ding, Yuan Chun
    Domchek, Susan M.
    [J]. GENETICS IN MEDICINE, 2020, 22 (10) : 1653 - 1666
  • [5] The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel
    Bernstein-Molho, Rinat
    Laitman, Yael
    Schayek, Hagit
    Reish, Orit
    Lotan, Shira
    Haim, Sara
    Zidan, Jamal
    Friedman, Eitan
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 697 - 702
  • [6] Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers
    Borde, Julika
    Ernst, Corinna
    Wappenschmidt, Barbara
    Niederacher, Dieter
    Weber-Lassalle, Konstantin
    Schmidt, Gunnar
    Hauke, Jan
    Quante, Anne S.
    Weber-Lassalle, Nana
    Horvath, Judit
    Pohl-Rescigno, Esther
    Arnold, Norbert
    Rump, Andreas
    Gehrig, Andrea
    Hentschel, Julia
    Faust, Ulrike
    Dutrannoy, Veronique
    Meindl, Alfons
    Kuzyakova, Maria
    Wang-Gohrke, Shan
    Weber, Bernhard H. F.
    Sutter, Christian
    Volk, Alexander E.
    Giannakopoulou, Olga
    Lee, Andrew
    Engel, Christoph
    Schmidt, Marjanka K.
    Antoniou, Antonis C.
    Schmutzler, Rita K.
    Kuchenbaecker, Karoline
    Hahnen, Eric
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (07): : 893 - 899
  • [7] Second-generation PLINK: rising to the challenge of larger and richer datasets
    Chang, Christopher C.
    Chow, Carson C.
    Tellier, Laurent C. A. M.
    Vattikuti, Shashaank
    Purcell, Shaun M.
    Lee, James J.
    [J]. GIGASCIENCE, 2015, 4
  • [8] Coignard J., 2021, NAT COMMUN, V12, P1, DOI [10.1038/s41467-020-20314-w, DOI 10.1038/S41467-020-20314-W]
  • [9] Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect
    Cruz Guindalini, Rodrigo Santa
    Song, Andrew
    Fackenthal, James D.
    Olopade, Olufunmilayo I.
    Huo, Dezheng
    [J]. CANCER, 2016, 122 (12) : 1913 - 1920
  • [10] Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
    Easton, Douglas F.
    Pharoah, Paul D. P.
    Antoniou, Antonis C.
    Tischkowitz, Marc
    Tavtigian, Sean V.
    Nathanson, Katherine L.
    Devilee, Peter
    Meindl, Alfons
    Couch, Fergus J.
    Southey, Melissa
    Goldgar, David E.
    Evans, Gareth R.
    Chenevix-Trench, Georgia
    Rahman, Nazneen
    Robson, Mark
    Domchek, Susan M.
    Foulkes, William D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (23) : 2243 - 2257